Echinacea Versus Placebo Effect in Common Cold (Physician Echinacea Placebo)

PHASE3CompletedINTERVENTIONAL
Enrollment

719

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

August 31, 2008

Study Completion Date

April 30, 2013

Conditions
Common Cold
Interventions
DIETARY_SUPPLEMENT

Echinacea

Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. B) Echinacea angustifolia - 600 mg root yields 150 mg dried extract, standardized to contain 2.0 mg alkamides. Each batch of tablets is analyzed by Reversed Phase - High Peformance Liquid Chromatography to determine the levels of alkamides and caffeic derivatives present. Caffeic acid derivative levels are typically as follows: caftaric acid = 0.5 to 2.0 mg/tablet; cichoric acid = 3.4 to 8.5 mg/tablet; chlorogenic acid = \< 0.5 mg/tablet; dicaffeoyl quinic acids (including cynarin) = 0.7 to 2.0 mg/tablet; echinacoside = 1.0 to 1.7 mg/tablet

OTHER

Blinded placebo

Blinded placebo - Coated tablet

Trial Locations (1)

53706-1490

University of Wisconsin-Madison Department of Family Medicine, Madison

All Listed Sponsors
collaborator

National Center for Complementary and Integrative Health (NCCIH)

NIH

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Wisconsin, Madison

OTHER

NCT00065715 - Echinacea Versus Placebo Effect in Common Cold (Physician Echinacea Placebo) | Biotech Hunter | Biotech Hunter